Approval

Solepinib Wins Dual China Approval

China's NMPA approved HUTCHMED's solepinib for two adult indications: previously treated primary chronic immune thrombocytopenia and warm antibody autoimmune hemolytic anemia. The oral spleen tyrosine kinase inhibitor is reported to be the first domestically developed Syk inhibitor approved in China. The resubmitted immune thrombocytopenia application was accepted in February 2026, and the warm antibody autoimmune hemolytic anemia application was accepted in April 2026.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call